(Q35925640)

11 August 2017

1 reference

title

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance (English)

1 reference

11 August 2017

Michael H Davidson

1

1 reference

PubMed ID

15500414

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Drug Safety

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

6

1 reference

11 August 2017

547-557

1 reference

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

11 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Controversy surrounding the safety of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

21 January 2018

Safety of rosuvastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

The statin wars: why AstraZeneca must retreat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Dangers of rosuvastatin identified before and after FDA approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Rhabdomyolysis in association with simvastatin and amiodarone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.547

21 January 2018

Identifiers

DOI

10.1517/14740338.3.6.547

1 reference

11 August 2017

1 reference

PubMed ID

15500414